Clinical Trial Update: Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Brivanib in combination with 5-FU/LV and FOLFIRI for gastrointestinal cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Brivanib (brivanib)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Gastro-Intestinal Cancer | Phase 1 | Status: COMPLETED